Protection of azidothymidine-induced cardiopathology in mice by mildronate, a mitochondria-targeted drug

Basic and Clinical Pharmacology and Toxicology

Volumn 99, Issue 4, 2006, Pages 323-328

  Klusa, Vija ^a   Pupure, Jolanta ^a   Isajevs, Sergejs ^a   Rumaks, Juris ^a   Gordjushina, Valentina ^a   Kratovska, Aina ^a   Taivans, Immanuels ^a   Svirskis, Simons ^a   Viksna, Ludmila ^b   Kalvinsh, Ivars ^c  

^a UNIVERSITY OF LATVIA   (Latvia)

^b Infectology Centre of Latvia   (Latvia)

^c LATVIAN INSTITUTE OF ORGANIC SYNTHESIS   (Latvia)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MILDRONATE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SYNAPTOTAGMIN; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CELL DEGENERATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG TARGETING; HEART PROTECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MITOCHONDRIAL RESPIRATION; MOUSE; MYOCARDIAL DISEASE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CARDIOVASCULAR AGENTS; DISEASE MODELS, ANIMAL; HEART DISEASES; METHYLHYDRAZINES; MICE; MICE, INBRED ICR; MITOCHONDRIA; ZIDOVUDINE;

EID: 33750075751     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2006.pto_543.x     Document Type: Article

References (27)

1. Akahira, M., A. Hara & Y. Abiko: Effect of MET-88, a gamma-butyrobetaine hydroxylase inhibitor, on myocardial derangements induced by hydrogen peroxide in the isolated perfused rat heart. Fund. Clin. Pharmacol. 1997, 11, 356-364.
2. Akasaka, Y., N. Morimoto, Y. Ishikawa, K. Fujita, K. Ito, M. Kimuro-Matsumoto, S. Ishiguro, H. Morito, Y. Kobayashi & T. Ishii: Myocardial apoptosis associated with the expression of proinflammatory cytokines during the course of myocardial infarction. Mod. Pathol. 2006, 19, 558-598.
3. Badley, A. D., T. Roumier, J. J. Lum & G. Kroemer: Mitochondrion-mediated apoptosis in HIV-1 infection. Trends Pharmacol. Sci. 2003, 24, 298-305.
4. Brocklehurst, P. & J. Volmink: Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst. Rev. 2002, 2, CD003510.
5. Corcuera Pindado, M. T., A. Lopez Bravo, R. Martinez-Rodriguez, A. Picazo Talavera, F. Gomez Aguado, M. Roldan Contreras, M. J. Perez Alvarez, A. Fernandez Garcia & M. J. Alonso Martin: Histochemical and ultrastructural changes induced by zidovudine in mitochondria of rat cardiac muscle. Eur. J. Histochem. 1994, 38, 311-318.
6. Dambrova, M., E. Liepinsh & I. Kalvinsh: Mildronate: cardioprotective action through carnitine-lowering effect. Trends Cardiovasc. Med. 2002, 9, 155-159.
7. De la Asuncion, J. G., M. L. Del Olmo, L. G. Gomez-Cambronero, J. Sastre, F. V. Pallardo & J. Vina: AZT induces oxidative damage to cardiac mitochondria: protective effect of vitamins C and E. Life Sci. 2004, 76, 47-56.
8. Di Stefano, A., G. Caramori, T. Oates, A. Capelli, M. Lusuardi, I. Gnemmi, F. Ioli, K. F. Chung, C. F. Donner, P. J. Barnes & I. M. Adcock: Increased expression of nuclear factor-κB in bronchial biopsies from smokers and patients with COPD. Eur. Respir. J. 2002, 20, 556-563.
9. Domanski, M. J., M. M. Sloas, D. A. Follmann, P. P. Scalise, E. E. Tucker, D. Egan & P. A. Pizzo: Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus. J. Pediatr. 1995, 127, 137-146.
10. Frantz, S., D. Franccarollo, H. Wagner, T. M. Behr, P. Jung, C. E. Angermann, G. Ertl & J. Bauersashs: Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failure. Cardiovasc. Res. 2003, 57, 749-756.
11. Hanaki, Y., S. Sugiyama & T. Ozawa: Effect of 3-(2,2,2,- trimethylhydrazinium) propionate, gamma-butyrobetaine hydroxylase inhibitor, on isoproterenol-induced mitochondrial disfunction. Res. Commun. Chem. Phatol. Pharmacol. 1989, 64, 157-160.
12. Hayashi, Y., H. Ishida, M. Hoshiai, K. Hoshiai, T. Kirimoto, T. Kanno, M. Nakano, K. Tajima, H. Miyake, N. Matsuura & H. Nakazawa: MET-88, a gamma-butyrobetaine hydroxylase inhibitor, improves cardiac SR Ca2+ uptake activity in rats with congestive heart failure following myocardial infarction. Mol. Cell. Biochem. 2000, 209, 39-46.
13. Herdy, G. V., C. A. Pinto, V. G. Lopes, R. P. Ribeiro, I. M. Gomes, H. Y. Tchou, R. Melo, B. Kurdian & Pde A. Junior Tavares: Study of the cardiac alterations in HIV-infected children consequent to the antiretroviral therapy. Prospective study of 47 cases. Arq. Bras. Cardiol. 2003, 80, 311-320.
14. Hong, M., L. Schlichter & R. Bendayan: A novel zidovudine uptake system in microglia. J. Pharmacol. Exp. Therap. 2001, 176, 141-149.
15. Larsson, N. G. & A. Oldfors: Mitochondrial myopathies. Acta Physiol. Scand. 2001, 171, 225-233.
16. Lia, G., F. Labruto, A. Sirsjo, F. Chena, J. Vaage & G. Valena: Myocardial protection by remote preconditioning: the role of nuclear factor kappa-B p105 and inducible nitric oxide synthase. Eur. J. Cardiothor. Surg. 2004, 26, 968-973.
17. McCurdy, D. T. & J. M. Kennedy: AZT decreases rat myocardial cytochrome oxidase activity and increases beta-myosin heavy chain content. J. Mol. Cell. Cardiol. 1998, 18, 1979-1989.
18. Nusbaum, N. J. & P. E. Joseph: AZT incorporation into mitochondria: study in human myeloid cell line. DNA Cell Biol. 1996, 15, 363-366.
19. Peters, B. S., J. Winer, D. N. Landon, A. Stotter & A. J. Pinching: Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS. Quart. J. Med. 1993, 86, 5-15.
20. Radwan, M. A.: Zidovudine, diclofenac and ketoprofen pharmacokinetic interactions in rats. J. Pharm. Pharmacol. 2000, 52, 665-669.
21. Rahman, I. & W. MacNee: Oxidative stress and regulation of glutathione in lung inflammation. Eur. Respir. J. 2000, 16, 534-554.
22. Sesti, C., B. Z. Simkhovich, I. Kalvinsh & R. A. Kloner: Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting hemodynamics. J. Cardiovasc. Pharmacol. 2006, 47, 493-499.
23. Shutenko, Zh. B., D. Meirena, T. I. Kagan, N. I. Sjakste & I. Ya. Kalvinsh: [Mildronate: mechanisms of action, prospects in the correction of pathologic states]. Khimiko-Farmacevticheskij Zhurnal 1995, 29, 13-17 (in Russian).
24. Szabados, E., G. M. Fisher, K. Toth, B. Csete, B. Nemeti, K. Trombitas, T. Habon, D. Endrei & B. Sumegi: Role of reactive oxygen species and poly-ADP-ribose polymerase in the development of AZT-induced cardiomyopathy in rat. Free Radic. Biol. Med. 1999, 14, 309-317.
25. Valen, G., Z. Q. Yan & G. K. Hansson: Nuclear factor kappa-B and the heart. J. Amer. Coll. Cardiol. 2001, 38, 307-314.
26. Wright, G., I. S. Singh, J. D. Hasday, I. K. Farrance, G. Hall, A. S. Cross & T. B. Rogers: Endotoxin stress-response in cardiomyocytes: NF-kappaB activation and tumor necrosis factor-alpha expression. Amer. J. Physiol. Heart Circ. Physiol. 2002, 282, H872-H879.
27. Xuan, Y. T., X. L. Tang, S. Banerjee, H. Takano, R. C. X. Li, H. Han, Y. Qiu, J. J. Li & R. Bolli: Nuclear factor κB plays an essential role in the late phase of ischemic preconditioning in conscious rabbits. Circ. Res. 1999, 84, 1095-1109.